IDEA Group Consensus Statement on Medical Management of Adult Gender Incongruent Individuals Seeking Gender Affirmation as Male

Gender-affirming hormone therapy (GAHT) is the most frequent treatment offered to gender-incongruent individuals, which reduces dysphoria. The goal of therapy among gender-incongruent individuals seeking gender affirmation as male is to change their secondary sex characteristics to affect masculine physical appearances. GAHT greatly improves mental health and quality of life among gender incongruent individuals. India-specific guideline for appropriate care for gender-incongruent individuals is almost absent. This document is intended to assist endocrinologists and other healthcare professionals interested in gender incongruity for individuals seeking gender affirmation as male. A safe and effective GAHT regimen aims to effect masculinising physical features without adverse effects. In this document, we offer suggestions based on an in-depth review of national and international guidelines, recently available evidence and collegial meetings with expert Indian clinicians working in this field. Clinicians represented in our expert panel have developed expertise due to the volume of gender incongruent individuals they manage. This consensus statement provides protocols for the hormone prescribing physicians relating to diagnosis, baseline evaluation and counselling, prescription planning for masculinising hormone therapy, choice of therapy, targets for monitoring masculinising hormone therapy, clinical and biochemical monitoring, recommending sex affirmation surgery and peri-operative hormone therapy. The recommendations made in this document are not rigid guidelines, and the hormone-prescribing physicians are encouraged to modify the suggested protocol to address emerging issues.

[1]  M. den Heijer,et al.  The ENIGI (European Network for the Investigation of Gender Incongruence) Study: Overview of Acquired Endocrine Knowledge and Future Perspectives , 2022, Journal of clinical medicine.

[2]  W. Rosa,et al.  Perioperative Considerations for Person-Centered Gender-Affirming Surgery. , 2021, Advances in anesthesia.

[3]  S. Leemaqz,et al.  Weight gain and obesity rates in transgender and gender-diverse adults before and during hormone therapy , 2021, International Journal of Obesity.

[4]  R. Bluebond-Langner,et al.  Tips and Tricks in Gender-Affirming Mastectomy , 2021, Plastic and reconstructive surgery.

[5]  M. Parmar,et al.  Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2021, The Lancet.

[6]  M. den Heijer,et al.  Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years , 2021, The Journal of clinical endocrinology and metabolism.

[7]  Theresa A. Stangl,et al.  Is there a need for liver enzyme monitoring in people using gender-affirming hormone therapy? , 2021, European journal of endocrinology.

[8]  Christina Wang,et al.  Reflections on the T Trials , 2020, Andrology.

[9]  T. Dakić New Perspectives on Transgender Health in the Forthcoming 11th Revision of the International Statistical Classification of Diseases and Related Health Problems: An Overview of Gender Incongruence - Depathologization, Considerations and Recommendations for Practitioners. , 2020, Psychiatria Danubina.

[10]  N. Stachenfeld,et al.  Pathophysiological effects of androgens on the female vascular system , 2020, Biology of Sex Differences.

[11]  Cindy B. Yeoh,et al.  Considerations for Transgender Patients Perioperatively. , 2020, Anesthesiology clinics.

[12]  A. Pastuszak,et al.  Occurrence of Pulmonary Oil Microembolism After Testosterone Undecanoate Injection: A Postmarketing Safety Analysis , 2020, Sexual medicine.

[13]  Sujoy Ghosh,et al.  IDEA Group Consensus Statement on Medical Management of Adult Gender Incongruent Individuals Seeking Gender Reaffirmation as Female , 2020, Indian journal of endocrinology and metabolism.

[14]  M. Heijer,et al.  Vaginal bleeding and spotting in transgender men after initiation of testosterone therapy: A prospective cohort study (ENIGI). , 2020, International journal of transgender health.

[15]  J. Safer,et al.  Care of the Transgender Patient , 2019, Annals of Internal Medicine.

[16]  Beverly A. Gray,et al.  Approaches to Vaginal Bleeding and Contraceptive Counseling in Transgender and Gender Nonbinary Patients. , 2019, Obstetrics and gynecology.

[17]  J. Reiner,et al.  Cardiovascular Disease Risk Factors and Myocardial Infarction in the Transgender Population , 2019, Circulation. Cardiovascular quality and outcomes.

[18]  O. Ganor,et al.  Association of Surgical Risk With Exogenous Hormone Use in Transgender Patients: A Systematic Review , 2019, JAMA surgery.

[19]  J. Arcelus,et al.  Endocrinology of Transgender Medicine. , 2018, Endocrine reviews.

[20]  Christopher D Lopez,et al.  Total penile reconstruction: A systematic review. , 2018, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[21]  Jennifer J. Liang,et al.  ESTROGEN LEVELS DO NOT RISE WITH TESTOSTERONE TREATMENT FOR TRANSGENDER MEN. , 2018, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[22]  M. Murad,et al.  ENDOCRINE TREATMENT OF GENDER-DYSPHORIC/GENDER-INCONGRUENT PERSONS: AN ENDOCRINE SOCIETY CLINICAL PRACTICE GUIDELINE. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[23]  Clara P. Savage,et al.  Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients , 2017, The Journal of clinical endocrinology and metabolism.

[24]  C. Unger Hormone therapy for transgender patients , 2016, Translational andrology and urology.

[25]  Ruben A. Hopwood,et al.  Informed Consent in the Medical Care of Transgender and Gender-Nonconforming Patients. , 2016, AMA journal of ethics.

[26]  A. Majumder,et al.  Outcome and preferences in female-to-male subjects with gender dysphoria: Experience from Eastern India , 2016, Indian journal of endocrinology and metabolism.

[27]  H. Abdullah,et al.  STOP-Bang Questionnaire: A Practical Approach to Screen for Obstructive Sleep Apnea. , 2016, Chest.

[28]  A. Bazzocchi,et al.  Effects of three different testosterone formulations in female-to-male transsexual persons. , 2014, The journal of sexual medicine.

[29]  H. Carlson,et al.  Gynaecomastia—pathophysiology, diagnosis and treatment , 2014, Nature Reviews Endocrinology.

[30]  P. Lips,et al.  Conjectures concerning cross-sex hormone treatment of aging transsexual persons. , 2014, The journal of sexual medicine.

[31]  Sheree M. Schrager,et al.  Subcutaneous Testosterone: An Effective Delivery Mechanism for Masculinizing Young Transgender Men. , 2014, LGBT health.

[32]  S. Terada,et al.  Factors predicting psychiatric co-morbidity in gender-dysphoric adults , 2012, Psychiatry Research.

[33]  W. J. Meyer,et al.  Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7 , 2012 .

[34]  Michael G. Miller,et al.  Secondary exposure to testosterone from patients receiving replacement therapy with transdermal testosterone gels , 2012, Current medical research and opinion.

[35]  M. Munro,et al.  The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. , 2011, Fertility and sterility.

[36]  L. Gooren,et al.  Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. , 2008, European journal of endocrinology.

[37]  L. Gooren,et al.  The biology of human psychosexual differentiation , 2006, Hormones and Behavior.

[38]  Martin L. Lee,et al.  Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[39]  Patrick C. Walsh,et al.  American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.

[40]  P. V. van Kesteren,et al.  Long‐term follow‐up of bone mineral density and bone metabolism in transsexuals treated with cross‐sex hormones , 1998, Clinical endocrinology.

[41]  L. Gooren,et al.  Mortality and morbidity in transsexual patients with cross-gender hormone treatment. , 1989, Metabolism: clinical and experimental.

[42]  J. Collen,et al.  The Effects of Transgender Hormone Therapy on Sleep and Breathing: A Case Series. , 2019, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[43]  A. Majumder,et al.  Presentation of gender dysphoria: A perspective from Eastern India , 2016, Indian journal of endocrinology and metabolism.

[44]  G. Arbanas Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .

[45]  C. Unger Care of the transgender patient: the role of the gynecologist. , 2014, American journal of obstetrics and gynecology.

[46]  J. Kaufman,et al.  Short- and long-term clinical skin effects of testosterone treatment in trans men. , 2014, The journal of sexual medicine.

[47]  Masami Watanabe,et al.  Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder. , 2013, Endocrine journal.

[48]  C Rayner,et al.  Informed consent. , 2000, British journal of plastic surgery.